Aditxt Unveils bitXbio: A Bitcoin-Backed Strategy to Accelerate Biotech Commercialization and Unlock Shareholder Value.

Aditxt has unveiled its bitXbio Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin to support its biotech commercialization efforts. The plan includes a Bitcoin-backed treasury strategy, equity line facility, and planned capitalization events in 2026, aiming to expand Aditxt's capital ecosystem and align its enterprise value with projected monetization opportunities. The initiative is designed to broaden the company's capital accessibility and strengthen its balance sheet and enterprise value.

Title: Aditxt Unveils bitXbio Plan: Bitcoin-Backed Treasury Strategy to Support Biotech Commercialization

Aditxt, Inc. (Nasdaq: ADTX) has announced its bitXbio Plan, a next-generation capitalization and monetization strategy integrating Bitcoin (BTC) to support its biotech commercialization efforts. The plan, which includes a Bitcoin-backed treasury strategy and an equity line facility, aims to expand Aditxt's capital ecosystem and align its enterprise value with projected monetization opportunities starting in 2026.

The bitXbio Plan is designed to broaden the company's capital accessibility and strengthen its balance sheet and enterprise value. The initiative is anchored by a Bitcoin-backed treasury strategy, which will be established subject to the availability of funds. This strategy aims to align Aditxt's market value in support of its commercialization activities and unlock new opportunities with digital asset economies.

In addition to the Bitcoin-backed treasury strategy, Aditxt plans to strategically deploy capital drawn from its existing equity line facility. The equity line facility has approximately $125 million in availability, of which Aditxt has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025. This equity line facility will be utilized to meet existing financial obligations and support the company's commercialization roadmap and upcoming monetization events.

As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering. The plan reflects Aditxt’s broader vision to build a global, socially driven biotech platform capable of commercializing and monetizing innovation through digital capitalization.

Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The company's ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to "Make Promising Innovations Possible Together." Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement, Aditxt aims to introduce an additional program dedicated to women’s health.

The bitXbio Plan marks a significant step in Aditxt's strategic evolution, leveraging digital currencies to align its capital structure with the value-creation potential of its biotech pipeline. This forward-looking strategy positions the company to unlock shareholder value as it strives to execute on planned monetization milestones.

References
[1] https://www.stocktitan.net/news/ADTX/aditxt-unveils-bit-xbio-tm-a-bitcoin-backed-treasury-strategy-j8rd9vegt8u1.html
[2] https://www.ainvest.com/news/crypto-billionaire-cz-donates-10-million-bnb-buterin-biotech-projects-2507/